KIDS · Orthopediatrics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.36M | - | $61.25M | $61.08M | $52.41M | - | $54.57M | $52.80M | $44.69M | - |
| Cost of Revenue | $15.97M | - | $15.98M | $17.06M | $14.15M | - | $14.51M | $12.00M | $12.51M | - |
| Gross Profit | $43.39M | - | $45.27M | $44.02M | $38.26M | - | $40.06M | $40.80M | $32.17M | - |
| R&D | $2.23M | - | $2.33M | $2.16M | $2.35M | - | $2.58M | $2.54M | $3.00M | - |
| SG&A | $31.02M | - | $29.16M | $30.44M | $30.28M | - | $26.30M | $27.33M | $24.73M | - |
| Total Operating Expenses | $51.73M | - | $54.70M | $54.68M | $49.24M | - | $45.63M | $46.47M | $41.90M | - |
| D&A | $5.72M | - | - | - | $5.05M | - | - | - | $5.03M | - |
| Operating Income | ($8.34M) | - | ($9.43M) | ($10.66M) | ($10.98M) | - | ($5.57M) | ($5.67M) | ($9.72M) | - |
| Interest Expense | $1.68M | - | $2.00M | $1.28M | $1.27M | - | $10.0K | $421.0K | $339.0K | - |
| Income Tax | ($171.0K) | - | ($125.0K) | $49.0K | $196.0K | - | ($1.22M) | ($18.0K) | ($2.53M) | - |
| Net Income | ($10.69M) | - | ($11.77M) | ($7.11M) | ($10.66M) | - | ($7.92M) | ($6.03M) | ($7.80M) | - |
| EPS - Basic | ($0.45) | - | ($0.50) | ($0.30) | ($0.46) | - | ($0.34) | ($0.26) | ($0.34) | - |
| EPS - Diluted | ($0.45) | - | ($0.50) | ($0.30) | ($0.46) | - | ($0.34) | ($0.26) | ($0.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.19M | $19.56M | $16.83M | $44.55M | $33.44M | $43.82M | $51.05M | $28.93M | $21.60M | $31.05M |
| Accounts Receivable | $54.43M | $53.84M | $51.27M | $53.80M | $43.99M | $42.36M | $42.83M | $42.03M | $36.27M | $34.62M |
| Inventory | $134.02M | $133.79M | $128.81M | $125.27M | $119.75M | $117.00M | $120.93M | $116.37M | $112.69M | $105.85M |
| Accounts Payable | $19.70M | $18.79M | $7.16M | $12.69M | $14.20M | $8.91M | $11.65M | $17.00M | $19.74M | $12.65M |
| Current Assets | $245.87M | $256.42M | $245.85M | $257.70M | $232.06M | $237.17M | $248.31M | $193.78M | $203.72M | $226.50M |
| Total Assets | $502.19M | $508.63M | $493.49M | $503.61M | $470.25M | $473.21M | $489.29M | $430.76M | $437.19M | $438.75M |
| Current Liabilities | $47.18M | $46.20M | $33.23M | $38.67M | $37.51M | $33.96M | $34.63M | $39.57M | $45.82M | $41.67M |
| Long-term Debt | $100.39M | $99.82M | $99.17M | $97.00M | $73.03M | $72.96M | $72.51M | $9.78M | $10.15M | $9.91M |
| Total Liabilities | $163.48M | $162.03M | $144.18M | $148.09M | $123.10M | $118.64M | $118.38M | $59.47M | $66.60M | $61.72M |
| Stockholders' Equity | $338.71M | $346.60M | $349.31M | $355.51M | $347.15M | $354.57M | $370.92M | $371.29M | $370.58M | $377.02M |
| Retained Earnings | ($285.90M) | ($275.21M) | ($265.11M) | ($253.34M) | ($246.22M) | ($235.56M) | ($219.50M) | ($211.58M) | ($205.55M) | ($197.74M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.29M) | - | - | - | ($4.16M) | - | - | - | ($6.69M) | - |
| Investing Cash Flow | ($3.79M) | - | - | - | ($5.99M) | - | - | - | ($3.68M) | - |
| Financing Cash Flow | ($614.0K) | - | - | - | ($126.0K) | - | - | - | ($573.0K) | - |
| CapEx | $1.76M | - | - | - | $4.23M | - | - | - | $6.46M | - |
| Free Cash Flow | ($5.05M) | - | - | - | ($8.38M) | - | - | - | ($13.15M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 73.1% | - | 73.9% | 72.1% | 73.0% | - | 73.4% | 77.3% | 72.0% | - |
| Operating margin | -14.0% | - | -15.4% | -17.4% | -21.0% | - | -10.2% | -10.7% | -21.8% | - |
| EBITDA margin | -4.4% | - | - | - | -11.3% | - | - | - | -10.5% | - |
| Net margin | -18.0% | - | -19.2% | -11.6% | -20.3% | - | -14.5% | -11.4% | -17.5% | - |
| Free cash flow margin | -8.5% | - | - | - | -16.0% | - | - | - | -29.4% | - |
| FCF / Net income | 0.47 | - | - | - | 0.79 | - | - | - | 1.68 | - |
| R&D / Revenue | 3.8% | - | 3.8% | 3.5% | 4.5% | - | 4.7% | 4.8% | 6.7% | - |
| SG&A / Revenue | 52.3% | - | 47.6% | 49.8% | 57.8% | - | 48.2% | 51.8% | 55.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.1% | - | -2.4% | -1.4% | -2.3% | - | -1.6% | -1.4% | -1.8% | - |
| Return on equity | -3.2% | - | -3.4% | -2.0% | -3.1% | - | -2.1% | -1.6% | -2.1% | - |
| Return on invested capital | -1.5% | - | -1.7% | -1.9% | -2.1% | - | -1.0% | -1.2% | -2.0% | - |
| Liquidity | ||||||||||
| Current ratio | 5.21 | 5.55 | 7.40 | 6.66 | 6.19 | 6.98 | 7.17 | 4.90 | 4.45 | 5.44 |
| Quick ratio | 2.37 | 2.65 | 3.52 | 3.43 | 2.99 | 3.54 | 3.68 | 1.96 | 1.99 | 2.90 |
| Cash ratio | 0.26 | 0.42 | 0.51 | 1.15 | 0.89 | 1.29 | 1.47 | 0.73 | 0.47 | 0.75 |
| Leverage | ||||||||||
| Debt / Equity | 0.30 | 0.29 | 0.28 | 0.27 | 0.21 | 0.21 | 0.20 | 0.03 | 0.03 | 0.03 |
| Debt / Assets | 0.20 | 0.20 | 0.20 | 0.19 | 0.16 | 0.15 | 0.15 | 0.02 | 0.02 | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.0x | - | -4.7x | -8.3x | -8.7x | - | -556.6x | -13.5x | -28.7x | - |
| Equity multiplier | 1.48 | 1.47 | 1.41 | 1.42 | 1.35 | 1.33 | 1.32 | 1.16 | 1.18 | 1.16 |
| Liabilities / Assets | 0.33 | 0.32 | 0.29 | 0.29 | 0.26 | 0.25 | 0.24 | 0.14 | 0.15 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.12 | 0.12 | 0.11 | - | 0.11 | 0.12 | 0.10 | - |
| Inventory turnover | 0.12 | - | 0.12 | 0.14 | 0.12 | - | 0.12 | 0.10 | 0.11 | - |
| Days sales outstanding | 335d | - | 306d | 321d | 306d | - | 286d | 291d | 296d | - |
| Days inventory outstanding | 3063d | - | 2943d | 2680d | 3089d | - | 3041d | 3539d | 3288d | - |
| Days payable outstanding | 450d | - | 164d | 271d | 366d | - | 293d | 517d | 576d | - |
| Cash conversion cycle | 2947d | - | 3085d | 2730d | 3029d | - | 3035d | 3312d | 3008d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.1x | - | 1.3x | 1.4x | 1.6x | - | 1.7x | 1.8x | 1.8x | - |
| P / S | 6.3x | - | 7.1x | 8.2x | 10.9x | - | 11.5x | 12.6x | 14.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 13.3% | - | 12.2% | 15.7% | 17.3% | - | 36.5% | 33.5% | 41.5% | - |
| Revenue CAGR (3y) | 23.4% | - | 20.6% | 22.9% | 30.8% | - | 29.6% | 25.5% | 27.7% | - |
| Revenue CAGR (5y) | 22.6% | - | 22.5% | 35.1% | 26.2% | - | 21.3% | 23.7% | 25.0% | - |
| Gross profit growth (YoY) | 13.4% | - | 13.0% | 7.9% | 18.9% | - | 29.4% | 35.9% | 36.6% | - |
| Operating income growth (YoY) | 24.1% | - | -69.4% | -88.1% | -12.9% | - | -23.5% | -1.4% | -13.2% | - |
| Net income growth (YoY) | -0.3% | - | -48.7% | -18.0% | -36.6% | - | -72.5% | -108.9% | -14.7% | - |
| EPS growth (YoY) | 2.2% | - | -47.1% | -15.4% | -35.3% | - | -70.0% | -100.0% | -13.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 39.8% | - | - | - | 36.3% | - | - | - | -15.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2.4% | -2.2% | -5.8% | -4.2% | -6.3% | -6.0% | -0.9% | -2.4% | -0.7% | -0.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$236.35M totalTraumaand Deformity$166.30M · 70.4%
Spine$66.05M · 27.9%
Sports Medicine And Other$4.00M · 1.7%
Geographic
$236.35M totalUS$186.40M · 78.9%
Non Us$49.95M · 21.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ORTHOPEDIATRICS CORP against the 5 most active filers in the same SIC group.